Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands
Telzir 700 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. Pink film coated, capsule shaped, biconvex tablets, marked with GXLL7 on one side. |
Each film-coated tablet contains 700 mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg of amprenavir).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Fosamprenavir |
Fosamprenavir after oral administration, is rapidly and almost completely hydrolysed to amprenavir and inorganic phosphate prior to reaching the systemic circulation. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature noninfectious viral particles. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Tablet film-coat: Hypromellose |
HDPE bottles with a child resistant polypropylene closure containing 60 tablets.
ViiV Healthcare BV, Huis ter Heideweg 62, 3705 LZ Zeist, Netherlands
EU/1/04/282/001
Date of first authorisation: 12 July 2004
Date of renewal of authorisation: 15 May 2009
| Drug | Countries | |
|---|---|---|
| TELZIR | Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
